Menu
Search Close

Privacy Policy

Scancell Holdings PLC ("We") are committed to protecting and respecting your privacy. To view our Privacy Statement click here

 

Webcasts, Interviews and Media Coverage

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform

Wed, 23 May 2018 05:28:00

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.

A placing and subscription at 12 pence a share will account for £6mln of the total.

The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.

Wed, 18 Apr 2018 12:18:00

Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs

In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline

Wed, 18 Apr 2018 13:15:00